Screener
Regenxbio RGNX Other Service Revenue — Billed Contract Receivables
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:BilledContractReceivables.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current accounts receivable: | ||
| Billed to AbbVie for development milestone | $100,000 | — |
| Billed to other customers | 385 | 557 |
| Unbilled Novartis royalties | 4,124 | 23,806 |
| Unbilled Nippon Shinyaku services | 2,222 | 1,997 |
| Other unbilled | 23 | 19 |
| Current accounts receivable | 106,754 | 26,379 |
| Non-current accounts receivable: |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's other service revenue — billed contract receivables?
- Regenxbio (RGNX) reported other service revenue — billed contract receivables of $385K in Q2 2026.
- What does other service revenue — billed contract receivables mean?
- This metric represents the outstanding accounts receivable balance specifically associated with services provided under contractual agreements within the company's non-core or ancillary service segments. It captures the value of services delivered for which the company has recognized revenue but has not yet received cash payment from the counterparty. Monitoring this balance provides insight into the company's ability to collect on service-related contracts and the credit risk associated with its service-based revenue streams.
Ask your AI about Regenxbio's other service revenue — billed contract receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude